Pharma Mar Stock Price, News & Analysis (OTCMKTS:PHMMF)

$2.74 -0.04 (-1.44 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$2.74
Today's Range$2.74 - $2.78
52-Week Range$2.55 - $4.80
Volume1,968 shs
Average Volume9,815 shs
Market Capitalization$618.97 million
P/E RatioN/A
Dividend YieldN/A

About Pharma Mar (OTCMKTS:PHMMF)

Pharma Mar logoPharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. It develops and commercializes YONDELIS, a novel, multimodal, synthetically produced antitumor agent for the treatment of advanced soft tissue sarcomas as a single-agent, as well as for relapsed ovarian cancer in combination with Doxil/Caelyx. The company also has three other clinical-stage programs, including PM1183, plitidepsin, and PM184, which are under development for various types of solid and hematological cancers. In addition, it engages in molecular diagnostics; researching therapeutic applications of gene silencing; and chemical business. The company was founded in 1986 and is based in Madrid, Spain.

Receive PHMMF News and Ratings via Email

Sign-up to receive the latest news and ratings for PHMMF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$200.26 million
Price / Sales3.05
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares222,650,000

Pharma Mar (OTCMKTS:PHMMF) Frequently Asked Questions

What is Pharma Mar's stock symbol?

Pharma Mar trades on the OTCMKTS under the ticker symbol "PHMMF."

Who are some of Pharma Mar's key competitors?

How do I buy Pharma Mar stock?

Shares of Pharma Mar can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharma Mar's stock price today?

One share of Pharma Mar stock can currently be purchased for approximately $2.74.

How big of a company is Pharma Mar?

Pharma Mar has a market capitalization of $618.97 million and generates $200.26 million in revenue each year.

How can I contact Pharma Mar?

Pharma Mar's mailing address is Avda. De los Reyes 1 Pol. Ind. La Mina, Madrid U3, 28770. The company can be reached via phone at 34-91-846-6000.

MarketBeat Community Rating for Pharma Mar (PHMMF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  110
MarketBeat's community ratings are surveys of what our community members think about Pharma Mar and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pharma Mar (OTCMKTS:PHMMF) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Earnings History for Pharma Mar (OTCMKTS:PHMMF)

No earnings announcements for this company have been tracked by


Pharma Mar (OTCMKTS:PHMMF) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.07 EPS


Dividend History for Pharma Mar (OTCMKTS:PHMMF)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Pharma Mar (OTCMKTS PHMMF)

No insider trades for this company have been tracked by


Pharma Mar (OTCMKTS PHMMF) News Headlines


SEC Filings

Pharma Mar (OTCMKTS:PHMMF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Pharma Mar (OTCMKTS PHMMF) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.